ASKA Pharmaceutical Holdings Co., Ltd.
4886・Prime Market・Pharmaceuticals
Governance
As a company with a Board of Corporate Auditors, the company separates management and execution through an executive officer system, and has 4 outside directors and 2 outside corporate auditors. At the Ordinary General Meeting of Shareholders scheduled for June 24, 2026, the company plans to transition to a company with an Audit and Supervisory Committee, aiming to further increase the ratio of outside directors. As advisory bodies to the Board of Directors, the company has established a voluntary Group Nomination Committee and Group Compensation Committee, each chaired by an outside director.
Risk Management
The Group has established Crisis Management Regulations to prevent management crises through thorough communication to all employees and clarification of the responsibilities of officers and employees, while also establishing a system to immediately set up a response headquarters in the event of a crisis. Regarding ESG risks, the company identifies, evaluates, and manages them on a quarterly basis through a three-tier structure consisting of the Promotion Officers' Meeting, the ESG Promotion Committee, and the ESG Committee, and prioritizes them using Value Chain Mapping (VCM).
Shareholder Returns
From FY2027 (ending March 2027), the company will introduce a total payout ratio target of 40% and a progressive dividend policy. The annual dividend for FY2026 (ending March 2026) is ¥60 per share (interim ¥27 + year-end ¥33), with a consolidated payout ratio of 31.4%. For FY2027 (ending March 2027), a dividend of ¥65 (interim ¥32 + year-end ¥33) is planned.
Dividend Policy
The basic policy is to maintain stable, continuous dividends, and through FY2026 (ending March 2026) the company adopts a performance-linked profit distribution method targeting a consolidated payout ratio of 30%. Based on the "Notice Regarding Dividends of Surplus (Dividend Increase) and Change in Dividend Policy" disclosed on May 11, 2026, from FY2027 (ending March 2027) onward, the company will target a total payout ratio of 40% and introduce a progressive dividend policy (excluding special dividends). FY2026 (ending March 2026) results: interim dividend ¥27, year-end dividend ¥33, annual total ¥60, total dividend amount ¥1,703 million, consolidated payout ratio 31.4%. FY2027 (ending March 2027) forecast: interim dividend ¥32, year-end dividend ¥33, annual total ¥65, payout ratio forecast 38.4%.
ESG
The company promotes sustainability management through a three-tier structure comprising the ESG Committee, ESG Promotion Council, and Promotion Leaders' Council, and conducts climate change and natural capital disclosures in line with the TCFD and TNFD recommendations. The company targets a 60% reduction in CO₂ emissions by FY2035 (ending March 2036) compared to FY2013 (ending March 2014) levels. In terms of human capital, it has achieved a female manager ratio of 14.3% (against a 2030 target of 20%) and a male childcare leave uptake rate of 129.4%, and has been certified as an Excellent Enterprise of Health and Productivity Management for 8 consecutive years.
Last updated: June 19, 2026